Define the operating boundary
A useful definition names the triggering event, required inputs, governing source, accountable owner, decision or action, exception path, evidence retained, and downstream handoff. Buyers should adapt those elements to their own population, jurisdictions, policies, systems, and control model before writing requirements.
The most important distinction is between a label and an operational capability. A provider may document health-authority correspondence while depending on customer-supplied policy, licensed content, third-party data, integration partners, manual review, or services. The demonstration should expose those dependencies rather than hiding them behind a completed interface.
What a demonstration should prove
- Begin with representative source records and a named policy, standard, or controlled rule.
- Show the normal path, an ambiguous case, missing data, an exception, an override, and a material source change.
- Identify who can change rules, who can approve or reject, and how accountability is preserved.
- Trace every output back to inputs, versions, timestamps, user actions, and governing evidence.
- Export the resulting record and reconcile it with downstream systems and retained obligations.
Authority and operating context
FDA 21 CFR Part 11
Part 11 defines criteria under which FDA considers electronic records, electronic signatures, and handwritten signatures executed to electronic records trustworthy, reliable, and generally equivalent to paper records and handwritten signatures. Electronic quality and regulatory platforms frequently process predicate-rule records. Buyers must evaluate technical controls, procedural controls, intended use, record retention, audit trails, access, signatures, and system lifecycle together rather than accept a generic Part 11 badge.
eCTD v4.0
eCTD v4.0 defines a harmonised structure and exchange model for regulatory submissions, with regional controlled vocabularies, module-one requirements, validation criteria, transmission specifications, and implementation timelines maintained by authorities. RIM and publishing buyers need evidence for the exact regional implementation package, validation criteria, supported submission type, forward-compatibility phase, and release change process rather than a generic eCTD 4.0 claim.
ISO IDMP
The ISO IDMP family standardizes the identification and description of substances, dose forms and routes, units of measurement, regulated pharmaceutical products, and regulated medicinal products. EMA is implementing these concepts through substance, product, organization, and referential master-data services. IDMP readiness is a data-governance and operating-model question, not just a product feature. Buyers need to examine source ownership, data quality, terminology services, submission interfaces, stewardship, and change propagation.
Operating domains
Regulatory product and registration lifecycle
Risk that product, substance, device, market, registration, license, activity, authority, commitment, correspondence, and approval information is fragmented or too unreliable to support global regulatory decisions and market continuity.
Submission content and technical conformance
Risk that regulated content cannot be planned, authored, approved, assembled, validated, transmitted, received, and maintained in the correct format and lifecycle for the relevant authority and procedure.
Structured product data and labeling governance
Risk that medicinal-product, device, substance, pack, presentation, identifier, label, and artwork data is inconsistent across source systems, submissions, authority databases, markets, safety processes, and supply operations.
Complaints, post-market quality, and safety handoffs
Risk that complaints, adverse-event indicators, product-quality complaints, vigilance, field actions, recalls, post-market surveillance, and regulatory reporting are delayed or fragmented across quality, safety, medical, regulatory, and commercial systems.
Evidence and comparison limits
Official provider documentation can establish product positioning. Provider confirmation can clarify package or availability. Independent observation requires a disclosed scenario, environment, date, inputs, and reproducible result. None of those sources alone establishes buyer-specific legal, clinical, regulatory, quality, or operational fitness.
Buyer questions
- What exact outcome and evidence should health-authority correspondence produce?
- Which source, version, and customer facts govern the workflow?
- Which decisions remain human and who is accountable for them?
- What is native, configured, integrated, service-delivered, or planned?
- How does a changed source affect open and historical records?
Recent changes
EMA releases minor human and veterinary MAA eAF 1.28 versions — Regulatory operations teams need controlled form-version selection, documented transition dates, testing, and reconciliation with PMS and PLM eAF workflows.
FDA updates eCTD v4.0 regional and conformance materials — Sponsors and regulatory operations teams should recheck supported package versions, controlled vocabulary, technical validation, release timing, and internal change-assessment evidence.
EMA documents release of the public PMS API beta — The release increases the testability and reuse of some authority product data but does not remove the need for internal master-data ownership, reconciliation, and controlled regulatory workflows.
First four EUDAMED modules become mandatory — Medical-device organizations need controlled data ownership and change propagation across quality, product, certificate, operator, and regulatory records.
Revised EU Variations Guidelines begin to apply — RIM systems and procedures need effective-dated classification, form, submission, implementation, and annual-update logic with clear provenance.